MUMBAI: Pharma company Cipla secured a tender worth $188.95 million for manufacturing anti-retroviral (ARV) drug for treating HIV/ AIDS, the company announced on Friday.The tender was awarded by Global Fund, an organisation working towards ending AIDS.
“The tender offered to us allows us to make HIV/AIDS treatment accessible to more than 140 countries through Global Fund,” Mr Subhanu Saxena, MD and CEO, Cipla Limited said in press release.
Cipla supplies subsidised drug for HIV/AIDS since 2001. It has successfully signed a Supplier Partnership Agreement as a ‘Panel Supplier’. This contract is effective from January 1 2015. The supplies will begin from quarter four of the financial year.
– Beacon Bureau